The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Gilead Sciences; Janssen
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Gilead Sciences; Roche
Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
 
Morton Coleman
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Bayer; Gilead Sciences
Speakers' Bureau - Celgene; Gilead Sciences; Pharmacyclics
Research Funding - Celgene; Gilead Sciences; Merck; Millennium; Pharmacyclics; Roche
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Vincent Ribrag
Honoraria - Bristol-Myers Squibb; Eisai; Gilead Sciences; Infinity Pharmaceuticals; PharmaMar
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; incyte; Infinity Pharmaceuticals; MSD; NanoString Technologies; PharmaMar
Research Funding - arGEN-X BVBA
Patents, Royalties, Other Intellectual Property - BAY1000394 studies on MCL
Expert Testimony - SERVIER
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Roche
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lilly; Merck Serono; MSD; Sanofi
 
Douglas James DeMarini
Employment - GlaxoSmithKline; Incyte
Stock and Other Ownership Interests - GlaxoSmithKline; Incyte
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
 
Pier Luigi Zinzani
No Relationships to Disclose